Skip to main content
OpenTrials
Completed

NCT Number: NCT04556838

Study of VVN001 Ophthalmic Solution in Dry Eye Disease

This is a Phase 2a, multi-center, double-masked, randomized, vehicle-controlled, parallel-group study designed to evaluate the safety and tolerability and to explore the efficacy activity of VVN001 ophthalmic solution versus vehicle in subjects with dry eye disease.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Lexitas

Durham, North Carolina, 27703, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Provide written informed consent prior to any study-related procedures .
  • Are 18 years of age or older.
  • Are willing and able to follow instructions and willing to be present for the required study visits for the duration of the study.
  • Have a best corrected visual acuity (BCVA), using corrective lenses if necessary, in the qualifying eye(s) of +0.7 or better as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) at the screening visit and randomization visit.
  • Have a history of dry eye disease in both eyes
  • Are currently using artificial tears and have been using within 30 days of the screening visit.
  • Have an Eye dryness score ≥40 at Visit 1 and ≥35 at Visit 2, one score for both eyes (0-100 point VAS)
  • Have ongoing dry eye disease in the same eye or both eyes, as defined by all of the following criteria in the study eye and the same eye at Visit 1 and Visit 2:
  • Inferior CFS (iCFS) score of ≥2 (NEI; 0-4 scale; using 0.5 unit increments)
  • Have a Schirmer score (without anesthesia) of ≥1 and ≤7 mm/5 min.

Exclusion criteria

  • Have a known hypersensitivity or contraindication to the IP or components of IP.
  • Have a Schirmer score (without anesthesia) of <1 or >7 mm/5 min in the study eye.
  • Have history of uncontrolled glaucoma, IOP over 21 mmHg in either eye at the screening visit or are being treated with eye drops for glaucoma in the study eye. Or the subject has had laser or surgery for glaucoma in the study eye within 90 days of the study.

Treatment and study plan

VVN001 Ophthalmic Solution 1%

Drug

VVN001 Ophthalmic Solution 1%

VVN001 Ophthalmic Solution 5%

Drug

VVN001 Ophthalmic Solution 5%

Vehicle

Drug

VVN001 Ophthalmic Solution Vehicle

Primary outcomes

  1. Inferior Corneal Fluorescein Staining

    Time frame: Day 84

    Mean change from baseline in Inferior corneal fluorescein staining. Negative number indicates improvement. Depending upon individual subject's baseline, this measure can range from -4 to +4.

Secondary outcomes

  1. Total Corneal Fluorescein Staining

    Time frame: Day 84

    Mean change from baseline in total corneal fluorescein staining Negative number indicates improvement. Depending upon individual subject's baseline, this measure can range from -20 to +20.

  2. Regional Corneal Fluorescein Staining

    Time frame: Day 84

    Mean change from baseline in temporal regional corneal fluorescein staining. Negative number indicates improvement. Depending upon individual subject's baseline, this measure can range from -4 to +4.

  3. Eye Dryness

    Time frame: Day 84

    Mean Change in Eye Dryness VAS. Negative number indicates improvement. Depending upon individual subject's baseline, this measure can range from -100 to +100..

Sponsors and collaborators

Lead sponsor

VivaVision Biotech, Inc

Industry

Registry information

Official study title

A Phase 2a, Double-Masked, Randomized, Vehicle-controlled Trial Evaluating the Safety and Efficacy Activity of 1% and 5% VVN001 Compared to Vehicle in Subjects With Dry Eye Disease

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Sep 21, 2020
Registry last updated
Dec 13, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.